Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity
Objectives. The quantification of synovitis is of great significance for follow-up in patients with rheumatoid arthritis (RA). This study aimed to validate the use of power Doppler ultrasonography (PDUS) for evaluating synovial vascularity and synovial hypertrophy for synovitis in patients with rheu...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2017/1658397 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551789336985600 |
|---|---|
| author | Ying-Chou Chen Chi-Hua Ko Jia-Feng Chen Chung-Yuan Hsu Wen-Chan Chiu Tien-Tsai Cheng |
| author_facet | Ying-Chou Chen Chi-Hua Ko Jia-Feng Chen Chung-Yuan Hsu Wen-Chan Chiu Tien-Tsai Cheng |
| author_sort | Ying-Chou Chen |
| collection | DOAJ |
| description | Objectives. The quantification of synovitis is of great significance for follow-up in patients with rheumatoid arthritis (RA). This study aimed to validate the use of power Doppler ultrasonography (PDUS) for evaluating synovial vascularity and synovial hypertrophy for synovitis in patients with rheumatoid arthritis treated with adalimumab. Materials and Methods. The synovial disease activity and vascularity of RA on both wrists (radio-carpal joint) were assessed using GS and PDUS to derive the composite US scores based on abnormal counts and severity. The relationship between each measure was determined. Results. The 71 patients who received adalimumab therapy had significantly decreased DAS28, ESR, and CRP. After one month, PD score decreased and then remained low for 12 months. Synovial hypertrophy did not change until 3–6 months after, when it started to improve (p=0.017). By multivariate analysis, sex, age, BMI, and DAS28 did not lead to any difference between synovial hypertrophy and PDUS changes (p=0.498). Discussion. Composite US markers of synovial hypertrophy correlate significantly to the DAS28 score and ESR/CRP in adult RA. The time needed for synovial hypertrophy to decrease may be up to 3–6 months after adalimumab therapy. Switching to biological therapy before 3–6 months is inappropriate and ineffective. |
| format | Article |
| id | doaj-art-203e40201d314078aefbfb50bc8c6f6b |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-203e40201d314078aefbfb50bc8c6f6b2025-02-03T06:00:22ZengWileyMediators of Inflammation0962-93511466-18612017-01-01201710.1155/2017/16583971658397Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial VascularityYing-Chou Chen0Chi-Hua Ko1Jia-Feng Chen2Chung-Yuan Hsu3Wen-Chan Chiu4Tien-Tsai Cheng5Department of Rheumatology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDepartment of Rheumatology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDepartment of Rheumatology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDepartment of Rheumatology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDepartment of Rheumatology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDepartment of Rheumatology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, TaiwanObjectives. The quantification of synovitis is of great significance for follow-up in patients with rheumatoid arthritis (RA). This study aimed to validate the use of power Doppler ultrasonography (PDUS) for evaluating synovial vascularity and synovial hypertrophy for synovitis in patients with rheumatoid arthritis treated with adalimumab. Materials and Methods. The synovial disease activity and vascularity of RA on both wrists (radio-carpal joint) were assessed using GS and PDUS to derive the composite US scores based on abnormal counts and severity. The relationship between each measure was determined. Results. The 71 patients who received adalimumab therapy had significantly decreased DAS28, ESR, and CRP. After one month, PD score decreased and then remained low for 12 months. Synovial hypertrophy did not change until 3–6 months after, when it started to improve (p=0.017). By multivariate analysis, sex, age, BMI, and DAS28 did not lead to any difference between synovial hypertrophy and PDUS changes (p=0.498). Discussion. Composite US markers of synovial hypertrophy correlate significantly to the DAS28 score and ESR/CRP in adult RA. The time needed for synovial hypertrophy to decrease may be up to 3–6 months after adalimumab therapy. Switching to biological therapy before 3–6 months is inappropriate and ineffective.http://dx.doi.org/10.1155/2017/1658397 |
| spellingShingle | Ying-Chou Chen Chi-Hua Ko Jia-Feng Chen Chung-Yuan Hsu Wen-Chan Chiu Tien-Tsai Cheng Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity Mediators of Inflammation |
| title | Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity |
| title_full | Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity |
| title_fullStr | Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity |
| title_full_unstemmed | Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity |
| title_short | Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity |
| title_sort | anti tnf alpha adalimumab therapy had time lag of improvement in synovial hypertrophy compared to rapid response in power doppler synovial vascularity |
| url | http://dx.doi.org/10.1155/2017/1658397 |
| work_keys_str_mv | AT yingchouchen antitnfalphaadalimumabtherapyhadtimelagofimprovementinsynovialhypertrophycomparedtorapidresponseinpowerdopplersynovialvascularity AT chihuako antitnfalphaadalimumabtherapyhadtimelagofimprovementinsynovialhypertrophycomparedtorapidresponseinpowerdopplersynovialvascularity AT jiafengchen antitnfalphaadalimumabtherapyhadtimelagofimprovementinsynovialhypertrophycomparedtorapidresponseinpowerdopplersynovialvascularity AT chungyuanhsu antitnfalphaadalimumabtherapyhadtimelagofimprovementinsynovialhypertrophycomparedtorapidresponseinpowerdopplersynovialvascularity AT wenchanchiu antitnfalphaadalimumabtherapyhadtimelagofimprovementinsynovialhypertrophycomparedtorapidresponseinpowerdopplersynovialvascularity AT tientsaicheng antitnfalphaadalimumabtherapyhadtimelagofimprovementinsynovialhypertrophycomparedtorapidresponseinpowerdopplersynovialvascularity |